GlassScriptPhysician profile
Marcus A Norris
NPI 1962591362
$7,272.39
in general payments reported to CMS, 2019-2025
52 companies · $2,813 in 2025
The $2,813 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $459 · 2023: $688 · 2024: $3,313 · 2025: $2,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,529 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,528.85 |
| Education | $284.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $575.30 | 2023-2025 | Enhertu, Imfinzi, Lynparza |
| Gilead Sciences, INC. | $574.28 | 2023-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $499.67 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $475.44 | 2023-2025 | Tecvayli, Darzalex, Erleada |
| Novartis Pharmaceuticals Corporation | $450.82 | 2023-2025 | |
| Pfizer INC. | $390.59 | 2023-2025 | |
| Glaxosmithkline, LLC. | $369.41 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Eisai INC. | $325.05 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $301.37 | 2022-2025 | Ninlaro, Iclusig |
| Lilly USA, LLC | $272.33 | 2023-2025 | Jaypirca, Verzenio |
| Celgene Corporation | $235.64 | 2024-2025 | Reblozyl, Pomalyst |
| Astellas Pharma US INC | $195.83 | 2023-2025 | Vyloy, Padcev, Xospata |
| E.R. Squibb & Sons, L.L.C. | $192.82 | 2024-2025 | Opdualag, Opdivo |
| Abbvie INC. | $190.14 | 2023-2025 | |
| Taiho Oncology, INC. | $147.40 | 2024-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $146.96 | 2022-2023 | Tukysa |
| Incyte Corporation | $138.03 | 2024-2025 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $134.09 | 2022-2023 | Imbruvica |
| Beigene USA, INC. | $132.45 | 2024-2025 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $103.95 | 2023-2025 | Polivy, Venclexta, Columvi |
| Sumitomo Pharma America, INC. | $87.83 | 2023-2025 | Orgovyx |
| Tersera Therapeutics LLC | $79.85 | 2023-2025 | Xermelo, Zoladex |
| Legend Biotech USA INC. | $78.28 | 2025 | Carvykti |
| Morphosys, US INC. | $74.05 | 2022 | |
| Jazz Pharmaceuticals INC. | $72.17 | 2022-2025 | |
| Exelixis INC. | $71.18 | 2023-2025 | Cabometyx |
| Tempus Ai, INC | $69.65 | 2024-2025 | Xt Cdx |
| Sobi, INC | $61.55 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $57.98 | 2024-2025 | Ultomiris |
| Array Biopharma INC | $57.65 | 2025 | Braftovi, Mektovi, Tukysa |
| Aveo Pharmaceuticals, INC. | $53.37 | 2023-2024 | Fotivda |
| Beone Medicines USA, INC. | $50.86 | 2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $50.12 | 2024 | Tavalisse, Rezlidhia |
| Geron Corporation | $49.62 | 2025 | Rytelo |
| Genmab U.S., INC. | $48.07 | 2024-2025 | Epkinly |
| Daiichi Sankyo INC. | $41.04 | 2022-2025 | Enhertu |
| Amgen INC. | $40.85 | 2022 | |
| Syndax Pharmaceuticals, INC. | $40.58 | 2025 | |
| Stemline Therapeutics INC. | $37.15 | 2024-2025 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $35.52 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.87 | 2025 | |
| Kyowa Kirin, INC. | $28.19 | 2022-2024 | Poteligeo |
| Adaptive Biotechnologies Corporation | $27.14 | 2024 | Clonoseq |
| Emd Serono, INC. | $24.74 | 2025 | |
| Recordati_rare_diseases_inc. | $22.67 | 2024 | Sylvant |
| Regeneron Healthcare Solutions, INC. | $22.47 | 2025 | Libtayo |
| Azurity Pharmaceuticals, INC. | $22.00 | 2025 | Danziten |
| Pharmaessentia USA Corporation | $18.97 | 2024 | Besremi |
| Janssen Pharmaceuticals, INC | $17.45 | 2024 | Xarelto |
| Genzyme Corporation | $16.47 | 2025 | |
| Pharmacosmos Therapeutics INC. | $15.96 | 2024 | Cosela |
| Caris Mpi, INC. | $13.52 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.